SCHEMBL3384919

SCHEMBL3384919

CC(C)c1cnc(Nc2cccc(F)c2)nc1NCCCN

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ STK17A Q9UEE5 18/20 0.57
▸ STK17B O94768 10/20 0.57
▸ TBK1 Q9UHD2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387114 0.85 TBK1 (0.66) STK17ASTK17BTBK1
SCHEMBL3383665 0.84 TBK1 (0.65) STK17ASTK17BTBK1
SCHEMBL3384911 0.84 TBK1 (0.51) TBK1
SCHEMBL3383882 0.81 TBK1 (0.69) STK17ASTK17BTBK1
SCHEMBL3389031 0.80 TBK1 (0.58) STK17ASTK17BTBK1
Hydrochloric Acid SCHEMBL3388695 0.80 TBK1 (0.68) STK17ASTK17BTBK1
SCHEMBL13432220 0.79 TBK1 (0.80) STK17ATBK1
SCHEMBL16520165 0.79 TBK1 (0.54) STK17ASTK17BTBK1
SCHEMBL15584973 0.76 ULK1 (0.53) STK17ASTK17BTBK1
SCHEMBL15585056 0.76 STK17A (0.49) STK17ASTK17BTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 — — US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 STK17A 381/4885STK17B 595/4885TBK1 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback